Nanox Flags Going-Concern Doubt as Cash Falls to $26M
NNOX is trading near its 52-week low of $0.446 (3.4% above the low).
Summary
Nanox told investors its cash and deposits fell to roughly $26.0 million at September 30 from $60.0 million at year-end 2025, and management now says that balance is not enough to fund operations for at least the next 12 months — an explicit substantial-doubt going-concern statement. Preliminary Q3 revenue of $4.3-4.4 million did grow from $3.4 million a year ago, but teleradiology, still the bulk of the business, was flat at $3.1 million; the increase came from AI/software ($1.0 million vs $0.1 million) after consolidating Vaso Healthcare IT. This lands on top of a brutal stretch: a $40.7 million impairment and $55.5 million GAAP net loss in Q2, an $8 million direct offering priced at $1.00 in August, and a Nasdaq delisting notice on October 2 after shares traded below $1.00 for 30 days. With the stock near a 52-week low around $0.46 and the authorized-share increase still needing shareholder approval, the funding math is the whole story — another raise looks unavoidable and would come at deeply depressed prices. The Italy distribution deal for Nanox.AI's Bone Solution and the TIME Best Inventions nod for Nanox.ARC X are positive but immaterial against the liquidity problem.
At the time of this announcement, NNOX was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $0.45 to $4.71. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.